Skip to main content

Table 1 Patient characteristics

From: The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers

 

SLE, active renal disease

SLE, non-active renal disease

Diabetic nepharopathy

ANCA associated vasculitis

Number

19

79

74

11

Female/male, number

17/2

71/8

6/8

4/7

Age, years

31 (19 to 60)

44 (21 to 72)

58 (27 to 93)

63 (38 to 78)

SLEDAI

14 (11 to 23)

2 (0 to 10)

na

na

BVAS

na

na

na

5 (0 to 16)

Immunosuppresive treatment

19 × Pred 7 × Cyc, 1 × Aza 13 × HCQ, 2 × MMF

62 × Pred, 20 × Aza, 37 × HcQ, 15 × MMF, 3 × MTX, 3 xBelim, 1 × Flebo

1 × Rtx

9 × Pred, 1 × Cyc, 6 × Aza, 2 x Rtx

Prednisolone dose, mg, median (IQR)

40 (30 to 50)

5.0 (5.0 to 7.5)

-

5.0 (2.5 to 5.0)

  1. Values are mean (range) unless stated otherwise. Aza, azathioprine; Belim, belimumab; BVAS, Birmingham Vasculitis Activity Score; Cyc, pulse cyclophosphamide; HCQ, hydroxychloroquine; Flebo, flebogamma; MMF, mycophenolate mofetil; MTX, methotrexate; na, not applicable; Pred, prednisolone; Rtx, rituximab; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index.